Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421280 | 0.93 | NPSR1 (0.40) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL3218626 | 0.89 | LMNA (0.36) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL475955 | 0.89 | LMNA (0.36) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL3218630 | 0.89 | LMNA (0.36) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL768274 | 0.89 | LMNA (0.36) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL12157202 | 0.87 | LMNA (0.34) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL13482824 | 0.87 | LMNA (0.34) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL13482836 | 0.87 | LMNA (0.34) | NPSR1GLO1ALDH1A1GAALMNA | |
| SCHEMBL13568693 | 0.84 | RECQL (0.34) | CA2 | |
| SCHEMBL4421277 | 0.84 | RECQL (0.34) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361775-B2 | Process for the preparation of (S)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2008-04-22 | — | — | US | disclosed |
| EP-1678158-B1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2008-03-26 | — | — | EP | disclosed |
| EP-1673364-B1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2007-08-22 | — | — | EP | disclosed |
| US-20070129553-A1 | Process for the preparation of glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| CN-1863787-A | Process for the preparation of -glyceraldehyde acetonide | DSM IP ASSETS BV (NL) | 2006-11-15 | — | — | CN | disclosed |
| EP-1678158-A1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP Assets B.V. (NL) | 2006-07-12 | — | — | EP | disclosed |
| EP-1673364-A1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP Assets B.V. (NL) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040149-A1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS B.V. (NL) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005037819-A1 | PROCESS FOR THE PREPARATION OF (S)-GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS B.V. (NL) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073068-A1 | Process for the preparation of (s)-glyceraldehyde acetonide | AKR1C3, AK1, GAPDH | NPSR1 3114/4885GLO1 26/4885ALDH1A1 71/4885 |
| US-20070129553-A1 | Process for the preparation of glyceraldehyde acetonide | CA5A, GCG, CA5B | NPSR1 3969/4885GLO1 37/4885ALDH1A1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.